Patients Risk Health for Unapproved Weight-Loss Drug

An emerging weight-loss drug, retatrutide, is being sought on the gray market by individuals dissatisfied with currently available treatments. Despite lacking FDA approval, people like Henry are purchasing it online, primarily from Chinese vendors, to manage weight and related health issues like hypertension and sleep apnea.

Retatrutide's potential lies in its action as a 'triple agonist,' targeting GLP-1, GIP, and glucagon receptors. Clinical trials indicate substantial weight loss, with one study showing an average of 22% among participants taking the highest doses. This has fueled patient demand, with many seeking it after plateauing on other medications.

Medical professionals express concern over the self-prescription of retatrutide. Dr. David Shafer highlights the risks associated with using unregulated medications, stressing the need for medical monitoring of vital signs and patient response. Eli Lilly, the drug's manufacturer, is actively pursuing legal action against companies illicitly selling the drug, citing potential contamination and safety issues.

Access to retatrutide through official channels, like Eli Lilly's limited pre-approval program, is proving difficult for many patients. This arduous process leads some to seek alternative, riskier avenues. The unregulated nature of the gray market means consumers have no assurance of the drug's purity, potency, or safety, with documented cases of liver toxicity linked to mislabeled retatrutide products.